Vimarsana
Biggest News Aggregation in the World

Evan Loh News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Evan Loh. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Evan Loh Today - Breaking & Trending Today

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China's National Reimbursement Drug List -December 13, 2023 at 08:54 am EST - Vimarsana News

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China's National Reimbursement Drug List -December 13, 2023 at 08:54 am EST

BOSTON, Dec. 13, 2023 -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for life-threatening diseases and other...

Gurnet Point Capital and Novo Holdings Acquires Paratek Pharmaceuticals - Vimarsana News

Gurnet Point Capital and Novo Holdings Acquires Paratek Pharmaceuticals

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the company - Vimarsana News

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the company

Key Insights Significantly high institutional ownership implies Paratek Pharmaceuticals' stock price is sensitive to...

Source: yahoo.com
Antibiotic maker Paratek, low on cash, agrees to a buyout - Vimarsana News

Antibiotic maker Paratek, low on cash, agrees to a buyout

BioPharma

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Q1 2023 Earnings Call Transcript - Vimarsana News

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Q1 2023 Earnings Call Transcript

Operator: Greetings. And welcome to the Paratek Pharmaceuticals’ First Quarter 2023 Earnings Conference Call. As a reminder, this conference is being recorded, Tuesday, May 9, 2023.